Consolidated Statement Of Cash Flows

Solasia Pharma K.K. - Filing #7337315

Concept 2024-01-01 to
2024-03-31
2024-01-01 to
2024-03-31
2024-01-01 to
2024-03-31
2024-01-01 to
2024-03-31
2024-01-01 to
2024-03-31
2024-01-01 to
2024-03-31
2024-01-01 to
2024-03-31
2024-01-01 to
2024-03-31
As at
2024-03-31
As at
2023-12-31
2023-01-01 to
2023-03-31
2023-01-01 to
2023-03-31
2023-01-01 to
2023-03-31
2023-01-01 to
2023-03-31
2023-01-01 to
2023-03-31
2023-01-01 to
2023-03-31
2023-01-01 to
2023-03-31
2023-01-01 to
2023-03-31
As at
2023-03-31
As at
2022-12-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss)
JPY
-310,000,000 JPY
JPY
-310,000,000 JPY
JPY
JPY
JPY
JPY
JPY
-241,000,000 JPY
JPY
-241,000,000 JPY
JPY
JPY
JPY
JPY
Finance income
0 JPY
0 JPY
Finance costs
10,000,000 JPY
0 JPY
Share of loss (profit) of investments accounted for using equity method
0 JPY
1,000,000 JPY
Decrease (increase) in inventories
-20,000,000 JPY
-41,000,000 JPY
Other
-1,000,000 JPY
8,000,000 JPY
Subtotal
-163,000,000 JPY
226,000,000 JPY
Interest received
0 JPY
0 JPY
Interest paid
0 JPY
0 JPY
Net cash provided by (used in) operating activities
-164,000,000 JPY
223,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
JPY
0 JPY
Net cash provided by (used in) investing activities
JPY
0 JPY
Cash flows from financing activities
Proceeds from issuance of bonds
500,000,000 JPY
JPY
Proceeds from issuance of shares
249,000,000 JPY
JPY
Other
3,000,000 JPY
JPY
Net cash provided by (used in) financing activities
743,000,000 JPY
-12,000,000 JPY
Net increase (decrease) in cash and cash equivalents
579,000,000 JPY
210,000,000 JPY
Cash and cash equivalents
1,319,000,000 JPY
728,000,000 JPY
1,016,000,000 JPY
803,000,000 JPY
Effect of exchange rate changes on cash and cash equivalents
11,000,000 JPY
2,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.